Literature DB >> 28662713

The neutrophil-to-lymphocyte ratio (NLR) predicts adrenocortical carcinoma and is correlated with the prognosis.

Taku Mochizuki1, Takashi Kawahara2,3, Daiji Takamoto1, Kazuhide Makiyama4, Yusuke Hattori1, Jun-Ichi Teranishi1, Yasuhide Miyoshi1, Yasushi Yumura1, Masahiro Yao4, Hiroji Uemura1.   

Abstract

BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) is reported as a biomarker for some solid malignant diseases. Thus far, however, no reports of the relationship between the NLR and adrenal tumors have been published. We analyzed the utility of the preoperative NLR as a biomarker for predicting the prognosis or diagnosis of malignant disease.
METHODS: A total of 59 patients with adrenal tumors (13 cases of malignant disease and 46 with benign disease) were analyzed in this study from February 2004 to June 2015 at our institute. The NLR was obtained just before adrenalectomy. The diagnosis of adrenal tumor was confirmed by a pathological examination of surgical specimens.
RESULTS: The NLR in malignant adrenal tumor specimens was significantly higher than in non-malignant specimens (p = 0.028). Adrenocortical carcinoma (ACC) showed the highest NLR among all adrenal tumors. In ACC, the higher NLR group (NLR ≥ 5) showed a significantly poorer overall survival than the lower NLR group (NLR < 5) (p = 0.032).
CONCLUSIONS: In adrenal tumors, a higher NLR indicates a higher incidence of malignancy. The NLR might be a new biomarker for predicting the prognosis of adrenal tumor patients.

Entities:  

Keywords:  Adrenal tumor; Adrenocortical carcinoma; Biomarker; Neutrophil-to-lymphocyte ratio

Mesh:

Year:  2017        PMID: 28662713      PMCID: PMC5490233          DOI: 10.1186/s12894-017-0240-4

Source DB:  PubMed          Journal:  BMC Urol        ISSN: 1471-2490            Impact factor:   2.264


Background

Adrenocortical carcinoma (ACC) is a very rare disease with an incidence of 0.5 to 2.0 patients/100,000,000 patients/year and has one of the poorest prognoses among all solid malignancies [1, 2]. A large number of patients are diagnosed at an advanced stage. About 70% of ACCs are reported to be diagnosed as extra-adrenal lesions [3]. However, despite this poor prognosis, some patients have achieved a long disease-free survival [4]. There were no confirmed risk to predict a poorer prognosis. Several candidate prognostic factors of ACC have been reported, including the tumor size, rate of Ki-67 positivity, completeness of resection of the surgical margin, and the clinical stage [5]. A number of studies have revealed that the neutrophil-to-lymphocyte ratio (NLR) is an independent prognostic factor in various solid malignancies, including prostatic carcinoma and renal cell carcinoma [6, 7]. The NLR has also been suggested to be not only a predictor of the systemic inflammatory response in critical care patients but also a prognostic factor for certain solid malignancies [8-10]. The NLR can be easily calculated from routine complete blood counts (CBCs) in peripheral blood. The aims of this study were to compare the NLR in ACC patients with those in patients with other non-malignant adrenal tumors and to evaluate the NLR as a prognostic marker in ACC patients.

Methods

Patients

A total of 59 consecutive cases, including 33 adrenocortical adenoma, 13 pheochromocytoma, 9 adrenocortical cancer, and 4 malignant lymphoma, at our institute from February 2004 to June 2015 were analyzed in this study.

Clinical and laboratory assessments

The NLR was calculated using the neutrophil and lymphocyte counts obtained via CBCs just before adrenalectomy as part of the routine preoperative workup of patients. We set the cut-off point of 5.0 as the threshold defining an elevated NLR, in accordance with a previous report [11]. None of the patients demonstrated systemic inflammation or blood disease at the time of the blood examinations.

Statistical analyses

The patients’ characteristics were analyzed using the Mann-Whitney U and chi-squared tests. The cut-off NLR was determined based on the results of a receiver operative curve (ROC) analysis and a multivariate analysis was performed to investigate the factors associated with malignancy in adrenal tumors. Spearman’s correlation coefficients were calculated to investigate the correlation between the NLR and tumor size. The Kaplan-Meier product limit estimator was used to estimate the overall survival. A log-rank test was performed for comparison. The statistical analyses were performed using the Graph Pad Prism software program (Graph Pad Software, La Jolla, CA, USA). P values of <0.05 were considered to indicate statistical significance.

Results

We examined a total of 59 cases of adrenal tumor, including 33 cases of adrenal carcinoid (mean size, 22 mm; median (mean ± standard deviation) NLR, 2.84 (3.41 ± 1.89)), 13 cases of pheochromocytoma (mean size, 40 mm; NLR, 2.03 (2.47 ± 1.54)), nine cases of ACC (mean size, 100 mm; NLR, 6.02 (5.04 ± 3.09)), and four cases of malignant lymphoma (mean size, 91 mm; NLR, 3.30 (3.82 ± 2.18)) [Table 1]. Regarding the ACC cases, 8 (88.9%) were female and one (11.1%) was male. One of the four patients showed endocrine activity and capsule invasion. The median age was 64 years old, and the median follow-up period was 17 months. The ACC patients’ backgrounds, including the tumor volume and clinical stage, are shown in Table 2.
Table 1

Each adrenal tumor’s characteristics

adrenocortical adenomapheochromocytomaadrenocortical carcinomamalignant lymphoma
n331394
Sex (male: female)10: 236: 71: 83: 1
Age (median)50576470
Maximum tumor diameter (mm) (mean)224010091
NLR (median)2.842.036.023.30
Table 2

Adrenocortical carcinoma patients’ characteristics

NoAgeSexMaximum diameter (mm)Endocrine activityCapsule invasionClinical stageChemotherapyOutcomeObservation period (months)
185F96NAStageIVdead1
219F125++StageIII+dead5
364F72NAStageIV+dead42
462M100+StageIV+dead9
564F105NAStageIV+dead2
666F70+StageIV+dead30
742F108StageIV+dead17
834F125StageIVdead17
972F18+StageIalive27
Each adrenal tumor’s characteristics Adrenocortical carcinoma patients’ characteristics

NLR values and patient outcomes

Malignant adrenal tumors showed a significantly higher NLR (mean ± standard deviation, standard error of the mean: 4.76 ± 2.93, 0.81) than non-malignant adrenal tumors (3.01 ± 1.78, 0.27; p = 0.016). The NLR in ACC showed the highest NLR [Figs. 1 and 2]. The cut-off NLR for predicting malignant disease was 3.15 (area under ROC: 0.668) [Fig.3]. A multivariate analysis showed that the NLR was an independent predictor (GR 8.990, p: 0.037) (Table 3). The tumor size was weakly correlated with the NLR (r2: 0.08, p: 0.034). In ACC subjects, the higher NLR group (≥ 5) showed a significantly poorer overall survival than the lower NLR group (< 5) with a median survival of 174 vs. 917 days (p = 0.032) [Fig. 4].
Fig. 1

Comparison NLR of malignant adrenal tumor to NLR of non-malignant adrenal tumor

Fig. 2

Comparison NLR of adrenocortical carcinoma, pheochromocytoma, adrenal malignant lymphoma and adrenal adenoma

Fig. 3

Receiver operator characteristics curve to detect cut off point of NLR to detect malignant disease or not (area under ROC: 0.668)

Table 3

The results of the multivariate analysis

P valueHR95% CI
Gender (male)0.3320.3530.043–2.892
Age (≥57)0.0995.7200.719–45.504
NLR (≥3.15)0.0378.9901.142–70.547
Size (≥40 mm)<0.001112.4007.39–1710.5
Fig. 4

Overall survival of adrenocortical carcinoma according to the NLR

Comparison NLR of malignant adrenal tumor to NLR of non-malignant adrenal tumor Comparison NLR of adrenocortical carcinoma, pheochromocytoma, adrenal malignant lymphoma and adrenal adenoma Receiver operator characteristics curve to detect cut off point of NLR to detect malignant disease or not (area under ROC: 0.668) The results of the multivariate analysis Overall survival of adrenocortical carcinoma according to the NLR

Discussion

Recently, NLR had been shown to be an independent prognostic risk factor for certain solid malignancies [6-10]. Only one study comparing the NLR and the prognosis of ACC has been reported—by Bagante et al. [11]. They found that an NLR > 5.0 was associated with a poorer disease-specific survival and progression-free survival in ACC. No other reports have investigated the effectiveness of NLR in detecting the malignancy of an adrenal tumor. In the present study, we found that a higher NLR in adrenal tumors was associated with a higher incidence of malignancy. These findings might contribute to the prediction of malignant disease for differentiating incidentaloma. Among incidental adrenal tumors, ACC is difficult to diagnose using preoperative imaging findings. A tumor size >4 cm is a well-known imaging finding for differentiating malignant tumors, with a sensitivity of 81% [5]. A previous report showed that 16% of adrenal tumors with diameters of <5 cm were ACCs [12]. Due to the marked increase in the rate of imaging analyses being performed at medical check-ups, small ACC would be increased. So, differentiated diagnosis except tumor size would be needed. Irregular margins are usually seen in ACC, but some benign adrenal tumors also showed irregular margins [13]. Computed tomography (CT) shows a finding of a low Hounsfield unit value (< 10) with 98% specificity. Chemical-shift imaging with magnetic resonance imaging (MRI) has also been reported to be useful for detecting adrenal adenomas [14]. However, the specific imaging findings indicative of ACC remain unclear. The NLR can be easily calculated during a daily clinical examination. The combination of imaging findings on CT and/or MRI and the NLR may support the preoperative diagnosis of adrenal tumor. Previous reports have shown that an NLR > 5.0 indicates a poor prognosis in pancreas cancer and liver metastatic rectal cancer [15, 16]. Our previous study showed that an NLR > 2.4 was associated with a high risk of prostate cancer in patients with a PSA of 4–10 ng/mL [17]. However, due to the small number of patients, that study could not detect an adequate NLR cut-off point. In the present study, we found that an NLR cut-off point of 5.0 was adequate for predicting the prognosis of ACC. The cut-off NLR of 5.0 was the same as a previous report and was the median value in this study. The cut-off NLR of 5.0 was relatively high in comparison to other studies, which indicated the aggressive nature of ACC in comparison to other types of cancer. Further studies are needed to validate the clinical utility of this parameter. In this study, the multivariate analysis revealed that the tumor size and NLR were found to be independent predictors of malignant disease. The combination of the NLR and imaging findings might support the preoperative diagnosis and detection of malignant adrenal tumors, including ACC and malignant lymphoma, as well as benign adrenal tumors, helping in the planning of an adequate surgical approach. This study showed that an NLR of 5.0 was a candidate cut-off point for predicting the prognosis in ACC. In localized ACC, the surgical margin was confirmed to be the most important prognostic factor. The 5-year overall survival in completely surgically resected patients ranges from 40 to 50%, while the median overall survival in unresectable case is <1 year [6]. In cases preoperatively predicted to have a poor outcome, a preoperative surgical plan with extended resection might be suggested in order to obtain a negative surgical margin. This study was limited by its small sample size and retrospective nature, both due to the rarity of ACC. Further study is needed to confirm the usefulness of NLR in ACC to confirm the sensitivity and specificity.

Conclusion

Malignant adrenal tumors showed a higher NLR than non-malignant ones. In addition, the ACC patients with a higher NLR showed a significantly poorer survival than those with lower values.
  17 in total

1.  Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients.

Authors:  Basem Azab; Vijaya R Bhatt; Jaya Phookan; Srujitha Murukutla; Nina Kohn; Terenig Terjanian; Warren D Widmann
Journal:  Ann Surg Oncol       Date:  2011-06-03       Impact factor: 5.344

Review 2.  Adrenal imaging.

Authors:  Michael A Blake; Carmel G Cronin; Giles W Boland
Journal:  AJR Am J Roentgenol       Date:  2010-06       Impact factor: 3.959

3.  Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer.

Authors:  S R Walsh; E J Cook; F Goulder; T A Justin; N J Keeling
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

4.  Actual 10-year survivors following resection of adrenocortical carcinoma.

Authors:  Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides
Journal:  J Surg Oncol       Date:  2016-09-16       Impact factor: 3.454

5.  Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy.

Authors:  Tadayuki Kou; Masashi Kanai; Michio Yamamoto; Peng Xue; Yukiko Mori; Yasushi Kudo; Akira Kurita; Norimitsu Uza; Yuzo Kodama; Masanori Asada; Michiya Kawaguchi; Toshihiko Masui; Masaki Mizumoto; Shujiro Yazumi; Shigemi Matsumoto; Kyoichi Takaori; Satoshi Morita; Manabu Muto; Shinji Uemoto; Tsutomu Chiba
Journal:  Int J Clin Oncol       Date:  2015-06-28       Impact factor: 3.402

Review 6.  Adrenocortical carcinoma: clinical and laboratory observations.

Authors:  B L Wajchenberg; M A Albergaria Pereira; B B Medonca; A C Latronico; P Campos Carneiro; V A Alves; M C Zerbini; B Liberman; G Carlos Gomes; M A Kirschner
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

7.  Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey.

Authors:  Alicia C McDonald; Manish A Vira; Adriana C Vidal; Wenqi Gan; Stephen J Freedland; Emanuela Taioli
Journal:  Prostate       Date:  2014-01-16       Impact factor: 4.104

8.  The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer.

Authors:  Takeharu Yamanaka; Shigemi Matsumoto; Satoshi Teramukai; Ryota Ishiwata; Yoji Nagai; Masanori Fukushima
Journal:  Oncology       Date:  2008-04-17       Impact factor: 2.935

9.  Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma.

Authors:  Fabio Bagante; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2015-07-31       Impact factor: 3.454

10.  Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer.

Authors:  Takashi Kawahara; Yumiko Yokomizo; Yusuke Ito; Hiroki Ito; Hitoshi Ishiguro; Jun-ichi Teranishi; Kazuhide Makiyama; Yasuhide Miyoshi; Hiroshi Miyamoto; Masahiro Yao; Hiroji Uemura
Journal:  BMC Cancer       Date:  2016-02-16       Impact factor: 4.430

View more
  8 in total

1.  Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Possible Prognostic Markers for Patients Undergoing Resection of Adrenocortical Carcinoma.

Authors:  Mechteld C de Jong; Radu Mihai; Shahab Khan
Journal:  World J Surg       Date:  2020-11-21       Impact factor: 3.352

2.  Relationship between lymphocyte to monocyte ratio and brain metastasis in non-smalll cell lung cancer patients.

Authors:  Yafeng Liu; Chunxiao Hu; Jing Wu; Jiawei Zhou; Wenyang Wang; Xueqin Wang; Jianqiang Guo; Qingsen Wang; Xin Zhang; Jun Xie; Yingru Xing; Xuansheng Ding; Dong Hu
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

3.  Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy.

Authors:  Salvatore Grisanti; Deborah Cosentini; Marta Laganà; Alessandra Morandi; Barbara Lazzari; Laura Ferrari; Alberto Dalla Volta; Roberta Ambrosini; Vittorio Domenico Ferrari; Sandra Sigala; Alfredo Berruti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-24       Impact factor: 5.555

Review 4.  The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives.

Authors:  Maja Mizdrak; Tina Tičinović Kurir; Joško Božić
Journal:  Biomedicines       Date:  2021-02-10

5.  Comparison of the Effects of Low-flow and Normal-flow Desflurane Anaesthesia on Inflammatory Parameters in Patients Undergoing Laparoscopic Cholecystectomy.

Authors:  Tuğba Bingöl Tanrıverdi; Mehmet Tercan; Ayşe Güsun Halitoğlu; Ahmet Kaya; Gülçin Patmano
Journal:  Turk J Anaesthesiol Reanim       Date:  2020-11-30

6.  A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment.

Authors:  Takashi Kawahara; Masashi Kato; Kenichi Tabata; Ippei Kojima; Hiroshi Yamada; Osamu Kamihira; Hideyasu Tsumura; Masatsugu Iwamura; Hiroji Uemura; Yasuhide Miyoshi
Journal:  BMC Cancer       Date:  2020-09-25       Impact factor: 4.430

Review 7.  Serum Inflammation-based Scores in Endocrine Tumors.

Authors:  Pedro Marques; Friso de Vries; Olaf M Dekkers; Márta Korbonits; Nienke R Biermasz; Alberto M Pereira
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 5.958

8.  Prognostic Significance of Preoperative Albumin to Alkaline Phosphatase Ratio in Patients with Glioblastoma.

Authors:  Junhong Li; Mingrong Zuo; Xingwang Zhou; Yufan Xiang; Shuxin Zhang; Wentao Feng; Yanhui Liu
Journal:  J Cancer       Date:  2021-08-13       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.